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Objective. The molecular mechanisms underlying the association between obesity (BMI  30 kg/m2) and asthma are poorly understood. Since
shifts in the fate of bronchial cells due to low-grade systemic inflammation may provide a possible explanation, we investigated whether two of the
best documented functional variants in cell cycle control genes modify the obesity–asthma association.Methods.We genotyped 5930 SAPALDIA
cohort participants for the single-nucleotide polymorphisms (SNPs) rs9344 in the cyclin D1 gene (CCND1) and rs1042522 in the gene encoding
tumor protein 53 (TP53). We assessed the independent association of these SNPs and obesity with asthma prevalence and incidence. Results. The
CCND1 SNP modified the association between obesity and asthma prevalence (pinteraction ¼ 0.03). The odds ratios (ORs) and 95% confidence
intervals (CIs) for reporting a physician diagnosis of asthma at baseline, comparing obese with non-obese participants, were 1.09 (0.51–2.33), 1.64
(0.94–2.88), and 3.51 (1.63–7.53) for GG, GA, and AA genotypes, respectively. We found comparable genotype differences for incident asthma
within the 11 years of follow-up. As for the TP53 SNP, the interactions with obesity status with respect to asthma were not statistically significant.
Conclusions. Our results suggest that obesity may contribute to asthma and associated tissue remodeling by modifying the processes related to the
CCND1 gene activity.
Keywords candidate gene association study, cell proliferation genes, gene–lifestyle interaction, overweight, population-based cohort, single-
nucleotide polymorphism
INTRODUCTION
In many parts of the world, obesity prevalence is still
on the rise and represents a major public health concern.
Obesity increases the risk for later asthma (1), but the
underlying etiologic mechanisms for this epidemiologic
association remain poorly understood. Explanations
based solely on mechanistic effects of excessive
body weight seem insufficient, as other aspects of the
metabolic syndrome are also associated with impaired
lung function (2). Obesity-related inflammatory markers
or adipose derived hormones may influence bronchial
hyperresponsiveness (BHR) as well as airway inflamma-
tion and associated tissue remodeling, as demonstrated in
mouse models (3,4). But in human asthma studies, the data
in favor of an effect of these circulating molecules on
asthma risk remain inconclusive (5,6).
Investigating if gene variants of relevance to inflammatory
pathways modify the obesity–asthma association may
improve understanding of underlying etiologic mechanisms
involved. Currently, there are very few studies available in
adults which examine gene–obesity interactions with respect
to asthma (7). Candidate genes not yet looked at include those
essential to cell cycle control, as airway inflammation and
remodeling in asthmatics are associated with altered apopto-
sis and proliferation of different bronchial cells types such as
airway smoothmuscle (ASM) and epithelial cells, fibroblasts,
as well as cells of the immune system (8–11).
We therefore selected a functionally well-described
polymorphism in each of two genes crucial for cell divi-
sion in order to assess gene–obesity interactions in asthma
in a highly focused manner. The cyclin D1 gene (CCND1)
promotes cell proliferation through cell cycle G1–S phase
transition, while the tumor protein 53 gene (TP53) is a
tumor suppressor gene with a pivotal role in apoptosis. The
expression of both genes is commonly altered in numerous
cancer types. The single-nucleotide polymorphisms
(SNPs) rs9344 [P242P] in CCND1 and rs1042522
[R72P] in TP53 are functionally very well characterized
and have been associated with various cancer types,
including in large meta-analyses (12–14). We previously
demonstrated furthermore that these two polymorphisms
modified the effect of particulate matter (PM10) air pollu-
tion on lung function decline in the SAPALDIA cohort
(15). In this same cohort representing the general popula-
tion from eight Swiss communities, we now investigated
whether these two SNPs also affect asthma risk and its
relation to obesity. We argue that modification of the
asthma–obesity association by variants in cell cycle con-
trol genes adds to the evidence for a causal obesity effect,
mediated in part by inflammatory pathways.
*Corresponding author: Nicole Probst-Hensch, Ph.D., Head Unit Chronic
Disease Epidemiology, Swiss Tropical and Public Health Institute,
Socinstrasse 57, PO Box 4002 Basel, Switzerland; Tel: þ41 61 284 83 78
(direct);þ41 61 284 83 88 (admin); Fax:þ41 61 284 81 05; E-mail: Nicole.
Probst@unibas.ch
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METHODS
Study Population
Themethods of the SAPALDIA study have been described
in detail elsewhere (16,17). In short, the study population
consists of a random population sample of white adults
aged 18–60 years from eight areas of Switzerland. Totally,
9651 persons participated in the first assessment in 1991,
and at the follow-up examination in 2002, 8047 were
reassessed with a least a short screening questionnaire.
Blood donation and consent to genetic analyses at follow-
up was given by 6058 participants of whom 6040 led to
successful genotype determination. We could furthermore
not include 110 subjects who either had missing informa-
tion on asthma, smoking status or body mass index (BMI),
or reported an asthma diagnosis which had not been con-
firmed by a physician. Taken together, 3721 individuals of
the original study sample could not be considered for the
present analysis (hereinafter called non-participants). The
analyzed study sample consists hence of a total of 5930
participants. Written consent was obtained from all study
participants separately for each assessment procedure.
Approval of the study was given by the Swiss Academy
of Medical Sciences and the regional ethics committees.
Definition of Smoking Status, Asthma Status, and Obesity
At both surveys, participants underwent a detailed,
computer-assisted interview comprising questions
about smoking behavior, exposure to environmental
tobacco smoke, workplace exposure to dust and fumes,
co-morbidities including asthma, medication use, and
socio-economic factors. Never smokers were defined
as persons who at the time of the interview had smoked
less than 20 packs of cigarettes or 360 g of tobacco
during their lifetime. Former smokers reported quitting
at least one month before the interview. Asthmatics were
defined in two ways. First, physician-diagnosed asthma
was defined by affirmative answers to “Have you ever
had asthma?” and “Was this confirmed by a doctor?”
Second, current asthmatics, presenting a subset of those
who were diagnosed by a physician, were classified by
an affirmative answer to at least one of the following two
questions: “Have you had an attack of asthma in the last
12 months?” and “Are you currently taking any medi-
cines including inhalers, aerosols or tablets for asthma?”
Incident asthma was defined as a new report of
asthma among subjects without asthma at baseline.
BMI was divided into four categories: low BMI (BMI
< 20 kg/m2), normal weight (20 kg/m2  BMI <
25 kg/m2), overweight (25 kg/m2  BMI < 30 kg/m2),
and obese (BMI  30 kg/m2).
Genotyping
DNA extraction from EDTA-buffered whole blood has
been previously described (17). Originally, in each of
three candidate genes pivotal for cell cycle control
(CCND1, TP53, and CDKN1A, the gene encoding cyclin-
dependent kinase inhibitor 1A, also called p21), one pro-
mising candidate SNP was selected according to its
frequency and its reported functionality in cell division
and apoptosis (rs9344 in CCND1, rs1042522 in TP53,
and rs1801270 in CDKN1A). Genotyping was carried out
using fluorescent 5-nuclease real-time PCR methodology
(TaqMan, Applera Europe, Rotkreuz, Switzerland) and
ABI Prism 7900 sequence detection system (ABI,
Rotkreuz, Switzerland). The SNP-specific primers and
LNA® dual-labeled fluorogenic probes were designed by
Sigma Proligo (Evry, France). A 10% random sample of
all DNA samples was re-genotyped, and all genotypes
were confirmed. The genotype call rate was >99% for all
the three SNPs. Hardy–Weinberg equilibrium was pre-
served apart from rs1801270 (p ¼ 0.04). Since this latter
SNP also showed a low minor allele frequency
(MAF ¼ 7%), statistical power to investigate effects on
asthma and obesity was insufficient, and we excluded this
SNP from the analyses of this study.
Statistical Analysis
Main effects of alleles and BMI on physician-diagnosed
and current asthma at baseline were assessed using multi-
variate unconditional logistic regression. CCND1 and
TP53 genotypes were generally included in a co-dominant
fashion using the homozygous genotype of the more fre-
quent allele as the reference category. Due to the limited
number of TP53 CC carriers, this category was combined
with the group of heterozygous GC carriers for the ana-
lyses of incident asthma, assuming a dominant genetic
model. All regression models included study area, sex,
age at baseline, and smoking status (never vs. former vs.
current) at baseline as covariates. These factors were cho-
sen a priori as they may confound the obesity–asthma
association. Models investigating the longitudinal effects
of genotypes and change in BMI on incident asthma were
additionally adjusted for smoking status at follow-up.
Interaction between obesity and genotypes was tested by
integrating multiplicative terms in the regression models.
Significance levels for two-sided tests of main effects were
chosen at α ¼ 0.05, and at α ¼ 0.10 for tests of
effect modification. All statistical analyses were performed
using STATA version 10.1 (StataCorp, College Station,
TX, USA).
RESULTS
A detailed characterization of the study population can be
found in Table 1. Study participants were about half a year
older on average and had a slightly lower BMI than non-
participants. Totally, 6.2% declared to have ever received
an asthma diagnosis by a physician, whereas 2.6% suffered
from current asthma. These percentages were higher in
non-participants. Never smokers were more likely to be
included in this study, confirming that a sample with
higher health awareness was attracted to the follow-up
examination.
The cross-sectional associations of the genetic poly-
morphisms in CCND1 and TP53 with the prevalence of
asthma at baseline are presented in Table 2. The prevalence
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of physician-diagnosed asthma was lower among CCND1
rs9344 AA genotypes compared to homozygous GG indi-
viduals (p¼ 0.05), but this difference could not be detected
for current asthma. The polymorphism in TP53 was not
associated with either asthma phenotype.
By dividing the individuals into four BMI categories,
we confirmed the well-established association between
asthma and obesity (Table 3). Compared to those with
BMI between 20 and 25, obese individuals had a 1.81
times higher odds of having an asthma diagnosis by a
physician (p ¼ 0.003) and a 2.69 times higher odds of
suffering from current asthma (p < .001). Interestingly, the
cross-sectional association between asthma and obesity
depended on the genotype of the CCND1 SNP. The asso-
ciation of obesity with the risk of asthma was restricted to
the AA genotype as graphically displayed in Figure 1 for
physician-diagnosed asthma. Since low BMI and over-
weight did not essentially alter the odds of being an asth-
matic of normal weight people, we classified all non-obese
subjects (BMI < 30 kg/m2) into one category and com-
pared them with obese subjects. Overall, obese subjects
were 1.78 times (95% confidence interval (CI) 1.22–2.61)
more likely to report an asthma diagnosis confirmed by a
physician. For AA carriers of rs9344 in CCND1, this odds
ratio (OR) increased to 3.51 (95% CI 1.63–7.53). The
equivalent ORs for current asthma were even more pro-
nounced (overall OR 2.65, 95% CI 1.60–4.40; and for AA
carriers OR 7.17, 95% CI 2.89–17.83). Interaction terms
between CCND1 genotype and obesity were significant
for both asthma definitions (p ¼ 0.03 for physician-
diagnosed asthma and p ¼ 0.1 for current asthma). As
for rs1042522 in TP53, obesity tended to be more strongly
associated with the risk of asthma in homozygotes for the
G allele than in heterozygotes, but these differences were
based on very small sample sizes. When including BMI as
a continuous variable, we observed similar patterns of
associations.
Table 4 presents the longitudinal association of asthma
incidence with the change in obesity status during follow-
up. Obesity development was categorized into three dis-
tinct groups: participants who were never obese, partici-
pants who reached obesity at follow-up, and participants
who were obese at both times of data collection. The latter
group had the highest risk for developing asthma between
baseline and follow-up (OR 2.05 for physician-diagnosed
asthma and OR 2.58 for current asthma, compared to those
who were never obese). Stratification by CCND1 geno-
types modified this risk. We observed the highest risk
amongAA carriers (p< 0.001 for both asthma definitions).
Despite the wide confidence intervals, the p-values for
interaction between CCND1 genotype and obesity devel-
opment in relation to asthma incidence were marginally
statistically significant (p ¼ 0.09 for physician-diagnosed
asthma and p ¼ 0.03 for current asthma). The TP53 SNP
did not modify the association between obesity develop-
ment and asthma incidence.
Additional adjustment for atopy (positive skin prick
test), smoking intensity, early childhood infection,
family history of asthma, and exposure to gas, dust,
or fumes did not substantially alter the results (data
not shown).
TABLE 2.—Associations of genetic polymorphisms with asthma prevalence
at baseline.
Genotype N Prevalence (%) OR (95% CI) p-Value
Physician-diagnosed asthma
CCND1, rs9344
GG 1648 7.1 1
GA 2942 6.1 0.85 (0.66–1.08) 0.17
AA 1340 5.3 0.73 (0.54–0.99) 0.05
TP53, rs1042522
GG 3257 6.0 1
GC 2291 6.5 1.10 (0.88–1.36) 0.42
CC 382 5.5 0.89 (0.56–1.42) 0.62
Current asthma
CCND1, rs9344
GG 1648 2.5 1
GA 2942 2.6 1.05 (0.71–1.53) 0.82
AA 1340 2.8 1.09 (0.69–1.70) 0.72
TP53, rs1042522
GG 3257 2.5 1
GC 2291 3.0 1.21 (0.87–1.68) 0.26
CC 382 2.1 0.82 (0.39–1.70) 0.59
Notes: ORs were based on regression models adjusted for age, sex, study area, and
smoking status. OR, odds ratio; CI, confidence interval.
TABLE 1.—Baseline characteristics of participants and non-participants in this study.
Participants, N ¼ 5930 Non-participants
Mean SD % Mean SD % N (with info) p-Value
Female 50.2 51.8 3721 0.16
Age (years) 41.2 11.4 40.7 12.0 3721 0.06
BMI (kg/m2) 23.8 3.6 24.2 4.2 3622 <0.01
BMI  30 kg/m2 5.8 9.0 3622 <0.01
Physician-diagnosed asthma 6.2 7.8 3624 <0.01
Current asthma 2.6 3.4 3616 0.02
Smoking-status: never 47.3 38.5 3706
Smoking-status: former 23.1 21.7 3706 <0.01
Smoking-status: current 29.6 39.8 3706
Notes: Participants include all SAPALDIA follow-up subjects with valid information on sex, age, recruiting area, BMI, smoking status, and who could be successfully genotyped.
Answers to questions about self- and physician-diagnosed asthma, as well as recent asthma attacks and asthmamedication had to be complete and unambiguous. All SAPALDIA subjects
from the original study sample (N¼ 9651) who could not be considered in the present analysis were combined and referred to as non-participants. Equal proportions were tested by chi-
square test, equal distributions in age and BMI by Mann–Whitney test. SD, standard deviation; BMI, body mass index.
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DISCUSSION
We show for the first time that the cross-sectional and
longitudinal association of obesity and asthma is modified
by a SNP in a gene which exhibits a central role in cell
cycle control. The associations appear to be stronger
among subjects homozygous for the CCND1 A allele in
rs9344, the same genotype which in numerous studies
including a large meta-analysis predisposed to various
cancer subtypes across different ethnic populations (13).
According to our study, these participants’ lung tissue may
be more prone to remodeling in response to obesity-related
processes.
Asthma in Obese People
Our results confirm the well-established association of
obesity with asthma risk. Current knowledge include that
the obesity–asthma association decreases with progressive
age (18) and may in part be mediated by low-grade sys-
temic inflammation (19). Twin studies suggest that shared
genetic pathways for asthma and obesity may partly
explain the observed associations (20). Candidate gene
studies and, more recently, genome-wide association stu-
dies have identified a large number of genes associated
with either of the two conditions, but these genes do not
seem to have a substantial impact on both phenotypes
simultaneously (21). Candidate genes which seemed to
be important for the asthma risk in obese people or for
the higher BMI in asthmatics encompass LEP, TNFA, and
PRKCA, regions encoding the adipose tissue derived
TABLE 3.—Cross-sectional association of BMI with asthma risk at baseline, overall and stratified by CCND1 and TP53 genotypes.
Physician-diagnosed asthma Current asthma
BMI Yes/no OR 95% CI p-Value Yes/no OR 95% CI p-Value
All <20 40/712 0.85 0.59–1.22 0.38 16/736 0.80 0.45 to 1.39 0.42
20–25 195/3053 1 ref 81/3167 1 ref
25–30 98/1490 1.09 0.84–1.41 0.53 40/1548 1.11 0.75 to 1.66 0.60
30 33/309 1.81 1.22–2.68 0.003 19/323 2.69 1.59 to 4.56 <0.001
<30 333/5255 1 ref 137/5451 1 ref
30 33/309 1.78 1.22–2.61 0.003 19/323 2.65 1.60 to 4.40 <0.001
Continuous 366/5564 1.05 1.02–1.08 0.003 156/5774 1.08 1.04 to 1.12 <0.001
CCND1, rs9344 GG <30 109/1433 1 ref 39/1503 1 ref
30 8/98 1.09 0.51–2.33 0.83 3/103 1.20 0.35 to 4.09 0.77
Continuous 117/1531 0.98 0.93–1.04 0.55 42/1606 0.99 0.90 to 1.09 0.83
GA <30 163/2607 1 ref 69/2701 1 ref
30 15/157 1.64 0.94–2.88 0.08 8/164 2.07 0.97 to 4.44 0.06
Continuous 178/2764 1.06 1.02–1.10 0.005 77/2865 1.08 1.02 to 1.14 0.006
AA <30 61/1215 1 ref 29/1247 1 ref
30 10/54 3.51 1.63–7.53 0.001 8/56 7.17 2.89 to 17.83 <0.001
Continuous 71/1269 1.11 1.04–1.19 0.003 37/1303 1.17 1.07 to 1.28 <0.001
TP53, rs1042522 GG <30 172/2887 1 ref 68/2991 1 ref
30 23/175 2.41 1.50–3.87 <0.001 12/186 3.27 1.69 to 6.30 <0.001
Continuous 195/3062 1.06 1.02–1.11 0.002 80/3177 1.08 1.02 to 1.14 0.01
GC <30 142/2027 1 ref 63/2106 1 ref
30 8/114 1.04 0.49–2.19 0.92 5/117 1.59 0.62 to 4.11 0.34
Continuous 150/2141 1.01 0.96–1.06 0.68 68/2223 1.06 0.99 to 1.13 0.08
CC <30 19/341 1 ref 6/354 1 ref
30 2/20 2.45 0.46–13.03 0.29 2/20 8.29 1.05 to 65.36 0.05
Continuous 21/361 1.16 1.01–1.32 0.03 8/374 1.34 1.06 to 1.69 0.02
Notes: Regression models were adjusted for age, sex, study area and smoking status. p-Values for interaction between CCND1 genotype and obesity were 0.03 (physician-diagnosed
asthma) and 0.01 (current asthma). p-Values for interaction betweenCCND1 genotype and continuous BMI were 0.02 (physician-diagnosed asthma) and 0.03 (current asthma). p-Values
for interaction between TP53 genotype and obesity were 0.14 (physician-diagnosed asthma) and 0.64 (current asthma). p-Values for interaction between TP53 genotype and continuous
BMI were 0.86 (physician-diagnosed asthma) and 0.50 (current asthma). BMI, body mass index; OR, odds ratio; CI, confidence interval.
FIGURE 1.—Odds ratios (bars) and 95% confidence intervals (lines) for the
cross-sectional association of body mass index (BMI) category and
physician-diagnosed asthma stratified by CCND1 genotype. BMI categories
represent from darker to lighter color: <20 kg/m2, 20–25 kg/m2, 25–30
kg/m2, and 30 kg/m2. The reference group corresponded to individuals
with normal weight (BMI 20–25 kg/m2).
150 G. A. THUN ET AL.
J A
sth
m
a 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ity
 o
f B
as
el
 o
n 
03
/0
8/
13
Fo
r p
er
so
na
l u
se
 o
nl
y.
molecules leptin and tumor necrosis factor alpha (TNFα)
as well as the ubiquitously expressed protein kinase C
alpha, a factor associated with adipocyte differentiation
and insulin signaling (7,22,23). Cell cycle control genes
have so far not been investigated in this respect, but their
importance in inflammatory processes confer them etiolo-
gic plausibility to potentially modify the obesity–asthma
relationship. Interestingly, an in vitro study with asthma
serum-sensitized human ASM cells recently found protein
kinase C alpha to upregulate cyclin D1 expression (24).
Asthma: High Inflammatory Stress and Altered Cell Cycle
Control
In the present study, the CCND1 polymorphism rs9344
was associated with physician-diagnosed asthma at bor-
derline significance level, but not with current asthma.
This effect seems hence to originate from a history of
asthma or a form of asthma which does not manifest itself
in attacks on a regular basis. The inflammatory processes
in the bronchial tissue of untreated asthma lead to struc-
tural changes in the airways. Gene array techniques com-
paring gene expression profiles of various cell types in
bronchial tissue as well as in peripheral blood between
asthmatics and healthy controls exhibit significant differ-
ences in numerous genes (25). For instance, atopic asthma
has been associated with both reduced apoptosis of airway
inflammatory cells as well as reduced net TP53 activity
and thus reduced apoptosis of peripheral blood mononuc-
lear cells (8,26). ASM mass and cell proliferation is
increased in asthma (9), and this feature seems to involve
CCND1 the expression of which was elevated in asthma
serum-sensitized human ASM cells (24). A significant
suppression of bronchial epithelial cell proliferation asso-
ciated with increased CDKN1A expression was observed
in the asthmatic bronchial epithelium in humans (27).
Inherited differences in the cell cycle response to inflam-
matory and other oxidative stressors could hence in part
underlie asthma etiology. In agreement, asthma risk factors
with oxidative properties like tobacco smoke or air pollu-
tants were shown to alter cell proliferation in the airways
(28) and to alter lung function in a manner dependent on
cell cycle gene variants (15).
Obesity and Molecular Pathways of Potential Relevance
to Asthma
Obesity shares with some of the inhaled asthma triggers
the capacity to induce a status of low-grade systemic
inflammation. Diseases associated with over-nutrition are
characterized by alterations in circulating levels of inflam-
matory cytokines and adipose derived hormones (29). This
so-called metabolic inflammation interferes with the reg-
ulation of intracellular molecular pathways that include
cell cycle control mechanisms and could therefore also
play a role in asthma etiology.
The PI3K/Akt signal pathway is activated by many of
the factors which are altered in obesity and lead to
increased cell survival (30). This pathway is also crucial
in asthma pathophysiology. Namely, it has recently been
TABLE 4.—Longitudinal association of change in obesity status during follow-up with asthma incidence, overall and stratified by CCND1 and TP53 genotypes.
Incidence of physician-diagnosed asthma
(N ¼ 174 cases) Incidence of current asthma (N ¼ 115 cases)
BMI (baseline/follow up) Yes/no OR 95% CI p-Value Yes/no OR 95% CI p-Value
All <30/<30 145/4481 1 ref 89/4735 1 ref
<30/30 15/551 0.91 0.53–1.57 0.73 15/588 1.47 0.84–2.57 0.18
30/30 14/266 2.05 1.15–3.66 0.02 11/282 2.58 1.34–4.96 0.005
CCND1, rs9344
GG <30/<30 42/1231 1 ref 29/1309 1 ref
<30/30 2/140 0.46 0.11–1.94 0.29 1/158 0.30 0.04–2.28 0.24
30/30 4/85 1.90 0.63–5.74 0.25 3/90 1.73 0.50–6.05 0.41
GA <30/<30 80/2212 1 ref 45/2344 1 ref
<30/30 11/272 1.25 0.65–2.40 0.51 10/287 2.01 0.99–4.09 0.05
30/30 5/138 1.18 0.46–3.00 0.73 4/146 1.72 0.60–4.94 0.32
AA <30/<30 23/1038 1 ref 15/1082 1 ref
<30/30 2/139 0.68 0.16–3.01 0.61 4/143 2.24 0.71–7.11 0.17
30/30 5/43 8.86 2.82–27.81 <0.001 4/46 11.85 3.32–42.24 <0.001
TP53, rs1042522
GG <30/<30 85/2443 1 ref 53/2576 1 ref
<30/30 10/318 0.94 0.48–1.85 0.73 9/341 1.27 0.62–2.63 0.62
30/30 9/153 2.10 1.01–4.37 0.02 8/164 2.85 1.29–6.26 0.004
GC/CC <30/<30 60/2038 1 ref 36/2159 1 ref
<30/30 5/233 0.81 0.32–2.07 0.66 6/247 1.68 0.69–4.12 0.25
30/30 5/113 1.90 0.73–4.92 0.19 3/118 1.96 0.58–6.64 0.28
Notes: Included are participants without asthma at baseline (N¼ 5472 for physician-diagnosed asthma and N¼ 5720 for current asthma). Regression models were adjusted for age, sex,
study area, and smoking status at baseline and follow-up. GC and CC genotypes of rs1042522 were taken together since the number of these genotypes was very low. p-Values for
interaction between CCND1 genotype and obesity development were 0.09 (incidence of physician-diagnosed asthma) and 0.03 (incidence of current asthma). p-Values for interaction
between TP53 genotype and obesity development were 0.79 (incidence of physician-diagnosed asthma) and 0.68 (incidence of current asthma). BMI, body mass index; OR, odds ratio;
CI, confidence interval.
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shown that osteopontin, an extracellular matrix protein
upregulated in the lungs of asthmatics, activates the
PI3K/Akt pathway, and is associated with airway remodel-
ing and disease severity in human asthma (31,32).
The transcription factor nuclear factor kappa B
(NF-κB), one of the downstream targets of PI3K/Akt,
interacts with several adipose-derived molecules. For
instance, leptin stimulates and adiponectin reduces NF-
κB signaling in endothelial cells (33,34), while the cyto-
kine TNFα has been shown to interact with NF-κB signal-
ing in ASM cells (35). We previously reported a complex
joint effect of obesity with a TNFA polymorphism on
asthma in two large cohort studies including SAPALDIA
(7). NF-κB also exhibits a central role in the proliferating
airway epithelium of asthmatics (36). Its interplay with
different cell cycle control genes including TP53 and
CCND1 is diverse (37,38). Compatible with this picture,
leptin and adiponectin have also been found to be able to
modulate expression levels of cyclin D1 or p53 in different
types of cancer cells (39,40).
Both adiponectin and leptin are stimuli of the AMP-
activated protein kinase (AMPK) (41). AMPK serves as an
energy sensor and suppresses cell proliferation in non-
malignant and tumor cells by interacting with the cell
cycle machinery (42). As cell growth and proliferation
are energy-intensive processes, AMPK may act as an
energy checkpoint, permitting progression through the
cell cycle only in the presence of sufficient energy
reserves. Interestingly, metformin, an AMPK activator
used in the treatment of obesity-related diabetes, was
found to inhibit ASM cell proliferation (43).
Since obesity is also an established risk factor for colon
cancer and many of the described pathways and mechan-
isms are also discussed in the etiology of that disease (30),
results from colon cancer epidemiology are relevant to the
interpretation of our findings, as they support the notion
that cell cycle genes interact with inflammatory and other
oxidative stressors including obesity.We reported an inter-
acting effect on the risk of colorectal cancer for theCCND1
SNP studied in this work with dietary antioxidants and
proteins exhibiting antioxidative properties (44). Taken
together, these findings corroborate the view that (a)
obesity-mediated inflammation may directly affect cell
cycle control, proliferation, and apoptosis in a variety of
different tissues and that (b) the efficiency of these effects
can depend on polymorphisms in cell cycle control master
regulatory genes.
Strengths and Limitations of This Study
This study has several advantages. The study sample was
selected to be representative of the adult population in the
eight study areas. The study population is well character-
ized and comparatively large. Population stratification is at
best of minor influence since participants had to be local
residents for at least 3 years prior to the first survey, had to
show a good command of one of the national languages,
and there was no difference in genotype frequencies
between Swiss and non-Swiss citizens (p ¼ 0.88 for
rs9344 in CCND1 and p ¼ 0.26 for rs1042522 in TP53).
Moreover, stratification of the associations by study center
or language region did not materially alter the main find-
ings. The assessment of asthma relied on internationally
validated questions identical to those used in the European
Respiratory Health Survey (45).
Nevertheless, some limitations apply. Like in many
studies on asthma the definitions of asthma relied solely
on the self-report of asthma diagnosis, attacks, and medi-
cations. Asthma status may therefore be subject to mis-
classification. Furthermore, there is indication that obesity-
related asthma is a clearly distinct phenotype from general
asthma and should be addressed differently. In fact, tradi-
tional inflammatory mechanisms in the airways have not
been found to be relevant (6) and common asthma medica-
tion is far less helpful in obese subjects (46). Moreover, the
usually observed asthma remission after weight loss (47)
does not seem to support extensive airway remodeling.
However, it has been recently demonstrated that airway
remodeling may persist in asthmatics with complete
asthma remission (48).
We cannot exclude participation bias. Smokers and
patients with asthma and related phenotypes were less
likely to participate at follow-up. Respiratory health of
study participants is therefore slightly better than in non-
participants. However, unless participation of asthmatics
and non-asthmatics at baseline and follow-up was influ-
enced by one of the genotypes investigated, substantial
bias of the results due to non-participation is unlikely. A
further limitation is the absence of adequate data on phy-
sical activity. This does not allow us to properly differenti-
ate between modification of obesity and physical activity
by the genetic polymorphisms investigated.
The study focused on selected SNPs in the genes of
interest by giving priority to SNPs intensively studied in
cancer. The CCND1 rs9344 A allele leads to modulated
splicing and consequently elevated production of the
cyclin D1b isoform, a transcript with a higher cellular
transformation potential (49,50). Even though this isoform
is not solely dependent on rs9344, this polymorphism has
been associated with different types of cancer (12). Apart
from the high-penetrance mutations in TP53 that lead to
Li–Fraumeni syndrome, the non-synonymous SNP
rs1042522 is arguably the most likely with functional
relevance (14). The G allele is more powerful in inducing
apoptosis (51), and an analysis summarizing several stu-
dies looking at different types of cancer could find a
statistically marginally higher risk for carriers of the C
allele (52). Further functional studies on the protein level
are needed to clarify how the CCND1 and TP53 poly-
morphisms influence the cell division activity.
Finally, despite the large sample size of our study, the
statistical power became limited in some of the stratified
analyses, especially for the TP53 genotypes and asthma
incidence. Replication of the results in an independent
cohort study is therefore essential, and with the help of
pathway analysis involving many more SNPs and genes,
the importance of cell cycle control activity in the asthma–
obesity association could be more rigorously assessed.
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CONCLUSION
Since obesity is a worldwide rapidly growing phenom-
enon, it is of high public health relevance to clarify caus-
ality and mechanisms of its association with asthma. Our
results, if confirmed, suggest that obesity may contribute to
asthma and associated tissue remodeling by modifying
processes related to the CCND1 gene activity.
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